scispace - formally typeset
Journal ArticleDOI

Amyloid-β oligomers: their production, toxicity and therapeutic inhibition

Reads0
Chats0
TLDR
The role of cell-derived SDS-stable oligomers, their blocking of hippocampal long-term potentiation in vivo and the finding that this blocking can be prevented by prior treatment of oligomer-producing cells with gamma-secretase inhibitors are reviewed.
Abstract
Despite extensive genetic and animal modelling data that support a central role for the amyloid beta-protein (A beta) in the genesis of Alzheimer's disease, the specific form(s) of A beta which causes injury to neurons in vivo has not been identified. In the present study, we examine the importance of soluble, pre-fibrillar assemblies of A beta as mediators of neurotoxicity. Specifically, we review the role of cell-derived SDS-stable oligomers, their blocking of hippocampal long-term potentiation in vivo and the finding that this blocking can be prevented by prior treatment of oligomer-producing cells with gamma-secretase inhibitors.

read more

Citations
More filters
Journal ArticleDOI

A beta oligomers - a decade of discovery.

TL;DR: Accumulating evidence suggests that soluble forms of Aβ are indeed the proximate effectors of synapse loss and neuronal injury in Alzheimer’s disease.
Journal ArticleDOI

Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease.

TL;DR: New stereologic data indicate that neuronal pathology in hippocampal formation and frontal cortex closely reflects the progression of cognitive deficits in brain aging and AD, and demonstrate that amyloid volume has no additional predictive value, in terms of clinicopathologic correlations, beyond its interaction with NFT.
Journal ArticleDOI

Amyloid beta: structure, biology and structure-based therapeutic development

TL;DR: The structures, biological functions, and neurotoxicity role of Aβ are reviewed, the potential receptors that interact with Aβ and mediate Aβ intake, clearance, and metabolism are discussed, and the therapeutic developments and recent advances of different strategies for treating Alzheimer's disease are summarized.
Journal ArticleDOI

Inflammatory processes in Alzheimer's disease.

TL;DR: While inflammation has been thought to arise secondary to degeneration, recent experiments demonstrated that inflammatory mediators may stimulate APP processing by upregulation of beta secretase 1 and therefore are able to establish a vicious cycle.
Journal ArticleDOI

Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory.

TL;DR: Evidence is reviewed for a dedicated research effort aimed at understanding the behavioral consequences of altered levels and activity of the different APP fragments as a result of experience and disease, with particular attention to the contributions that APP fragments play in synaptic transmission and neural plasticity.
References
More filters
Journal ArticleDOI

Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease

TL;DR: Investigation revealed that Aβ40, whether in soluble or insoluble form, was a particularly useful measure for classifying ND, HPC, and AD patients compared with Aβ42, and it was found that concentrations of soluble Aβ clearly distinguished HPC from AD patients and were a strong inverse correlate of synapse loss.
Journal ArticleDOI

Properties of neurotoxic peptides related to the BRI gene

TL;DR: It is shown that the oxidized form of ABri and reduced form of ADan are toxic to human neuronal cell lines in culture and Neurotoxicity correlates with the extent of formation of SDS-stable non-fibrillar low-molecular-mass oligomers (SSNFOs).
Related Papers (5)